MX2022007094A - Compuestos para tratar la disautonomía familiar. - Google Patents
Compuestos para tratar la disautonomía familiar.Info
- Publication number
- MX2022007094A MX2022007094A MX2022007094A MX2022007094A MX2022007094A MX 2022007094 A MX2022007094 A MX 2022007094A MX 2022007094 A MX2022007094 A MX 2022007094A MX 2022007094 A MX2022007094 A MX 2022007094A MX 2022007094 A MX2022007094 A MX 2022007094A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- dysautonomy
- family
- treat
- present description
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947049P | 2019-12-12 | 2019-12-12 | |
| PCT/US2020/063612 WO2021118929A1 (en) | 2019-12-12 | 2020-12-07 | Compounds for treating familial dysautonomia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007094A true MX2022007094A (es) | 2022-07-11 |
Family
ID=74046197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007094A MX2022007094A (es) | 2019-12-12 | 2020-12-07 | Compuestos para tratar la disautonomía familiar. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230057568A1 (https=) |
| EP (1) | EP4072677A1 (https=) |
| JP (2) | JP2023506488A (https=) |
| KR (1) | KR20220113700A (https=) |
| CN (1) | CN115209955A (https=) |
| AU (1) | AU2020402717A1 (https=) |
| BR (1) | BR112022011364A2 (https=) |
| CA (1) | CA3160053A1 (https=) |
| CL (1) | CL2022001523A1 (https=) |
| CO (1) | CO2022008195A2 (https=) |
| IL (1) | IL293764A (https=) |
| MX (1) | MX2022007094A (https=) |
| PE (1) | PE20221581A1 (https=) |
| WO (1) | WO2021118929A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202108519TA (en) | 2019-02-13 | 2021-09-29 | Ptc Therapeutics Inc | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
| MX2024002887A (es) * | 2021-09-07 | 2024-05-28 | Ptc Therapeutics Inc | Metodos para tratar enfermedades neurodegenerativas. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1028964A1 (en) * | 1997-11-11 | 2000-08-23 | Pfizer Products Inc. | Thienopyrimidine and thienopyridine derivatives useful as anticancer agents |
| WO2005007083A2 (en) * | 2003-06-18 | 2005-01-27 | Smithkline Beecham Corporation | Chemical compounds |
| JP2009007341A (ja) * | 2007-06-01 | 2009-01-15 | Mitsubishi Tanabe Pharma Corp | 医薬組成物 |
| EP2014663A1 (de) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma AG | Thienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| EP2611812A1 (en) * | 2010-09-01 | 2013-07-10 | Ambit Biosciences Corporation | Thienopyridine and thienopyrimidine compounds and methods of use thereof |
| CN103242341B (zh) * | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用 |
| CA2973949C (en) * | 2015-01-16 | 2023-07-11 | The General Hospital Corporation | Compounds for improving mrna splicing |
| GB201700814D0 (en) * | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| WO2018151326A1 (ja) * | 2017-02-20 | 2018-08-23 | 国立大学法人京都大学 | スプライシング異常に起因する遺伝性疾病のための医薬組成物及び治療方法 |
| SG11202108519TA (en) * | 2019-02-13 | 2021-09-29 | Ptc Therapeutics Inc | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
| WO2020167624A1 (en) * | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
-
2020
- 2020-12-07 CN CN202080096472.5A patent/CN115209955A/zh active Pending
- 2020-12-07 CA CA3160053A patent/CA3160053A1/en active Pending
- 2020-12-07 AU AU2020402717A patent/AU2020402717A1/en not_active Abandoned
- 2020-12-07 MX MX2022007094A patent/MX2022007094A/es unknown
- 2020-12-07 JP JP2022535707A patent/JP2023506488A/ja active Pending
- 2020-12-07 WO PCT/US2020/063612 patent/WO2021118929A1/en not_active Ceased
- 2020-12-07 PE PE2022001057A patent/PE20221581A1/es unknown
- 2020-12-07 BR BR112022011364A patent/BR112022011364A2/pt not_active Application Discontinuation
- 2020-12-07 US US17/783,941 patent/US20230057568A1/en active Pending
- 2020-12-07 IL IL293764A patent/IL293764A/en unknown
- 2020-12-07 EP EP20829474.4A patent/EP4072677A1/en active Pending
- 2020-12-07 KR KR1020227019352A patent/KR20220113700A/ko not_active Ceased
-
2022
- 2022-06-09 CL CL2022001523A patent/CL2022001523A1/es unknown
- 2022-06-10 CO CONC2022/0008195A patent/CO2022008195A2/es unknown
-
2025
- 2025-06-11 JP JP2025097641A patent/JP2025133750A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020402717A1 (en) | 2022-06-23 |
| BR112022011364A2 (pt) | 2022-08-23 |
| WO2021118929A1 (en) | 2021-06-17 |
| KR20220113700A (ko) | 2022-08-16 |
| JP2025133750A (ja) | 2025-09-11 |
| CO2022008195A2 (es) | 2022-07-29 |
| CL2022001523A1 (es) | 2023-03-31 |
| US20230057568A1 (en) | 2023-02-23 |
| JP2023506488A (ja) | 2023-02-16 |
| CA3160053A1 (en) | 2021-06-17 |
| PE20221581A1 (es) | 2022-10-06 |
| IL293764A (en) | 2022-08-01 |
| CN115209955A (zh) | 2022-10-18 |
| EP4072677A1 (en) | 2022-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009667A (es) | Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar. | |
| MX2022007094A (es) | Compuestos para tratar la disautonomía familiar. | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| BR112023016299A2 (pt) | Composições e métodos para inibir kras | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| MX2022004101A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| BR112022016382A2 (pt) | Triptaminas específicas para o uso no tratamento de doenças do humor | |
| JOP20230284A1 (ar) | سيكلو ألكيل ٣_ أوكسو بيبرازين كربوكساميدات وسيكلو هيترو ألكيل ٣_ أوكسو بيبرازين كربوكساميدات كمثبطات nav1.8 | |
| EP2513343A4 (en) | METHOD AND COMPOSITIONS FOR TREATING SKIN INFLAMMATION | |
| BRPI0515931A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos | |
| BR112012012815A8 (pt) | composto derivado de 1,3-difenil-prop-2-en-1-ona, uso do referido composto, e composto, e, composição farmacêutica | |
| GEAP202215630A (en) | 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
| BRPI0408026A (pt) | Quinazolinas úteis como moduladores de canais de ìon | |
| CR20210544A (es) | DERIVADOS DE 1,1-DIÓXIDO DE 3-AMINO-4H-BENZO[E][1,2,4] tiadiazina COMO INHIBIDORES DE MRGX2 | |
| EP2576549A4 (en) | Bicyclic Heteroarylkinase Inhibitors and Methods of Use | |
| BR112014015720A2 (pt) | derivados de tieno[3,2-d]pirimidina que têm atividade inibidora de proteinas quinases | |
| BR0311784A (pt) | Composto, composição farmacêutica, métodos de tratar ou prevenir o câncer, de modular a formação do fuso mitótico e de inibir a cinesina mitótica e processo para fabricar uma composição farmacêutica | |
| CO6761350A2 (es) | Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis | |
| CO2020015377A2 (es) | Moduladores de la expresión de apol1 | |
| BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
| MX386873B (es) | Composiciones farmacéuticas y usos de las mismas para tratar enfermedades cardiovasculares | |
| CO2022017705A2 (es) | Composiciones y métodos para tratar trastornos asociados a mutaciones de pérdida de función en syngap1 | |
| CL2024000250A1 (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington | |
| DK1648484T3 (da) | Fremgangsmåde til behandling af arthritis-tilstande |